<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09143</article-id><article-id pub-id-type="doi">10.7554/eLife.09143</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Deconvoluting heme biosynthesis to target blood-stage malaria parasites</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-35279"><name><surname>Sigala</surname><given-names>Paul A</given-names></name><aff><institution content-type="dept">Department of Molecular Microbiology</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-35793"><name><surname>Crowley</surname><given-names>Jan R</given-names></name><aff><institution content-type="dept">Center for Women's Infectious Disease Research</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St. Louis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35794"><name><surname>Henderson</surname><given-names>Jeffrey P</given-names></name><aff><institution content-type="dept">Department of Molecular Microbiology</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St. Louis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-35280"><name><surname>Goldberg</surname><given-names>Daniel E</given-names></name><aff><institution content-type="dept">Department of Molecular Microbiology</institution>, <institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country><email>goldberg@wusm.wustl.edu</email></aff><xref ref-type="fn" rid="conf3"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1060"><name><surname>Clardy</surname><given-names>Jon</given-names></name><role>Reviewing editor</role><aff><institution>Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>07</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e09143</elocation-id><supplementary-material><ext-link xlink:href="elife-09143-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>02</day><month>06</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>07</month><year>2015</year></date></history><permissions><copyright-statement>Â© 2015, Sigala et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Sigala et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Heme metabolism is central to blood-stage infection by the malaria parasite, <italic>Plasmodium falciparum</italic>. Parasites retain a heme biosynthesis pathway but do not require its activity during infection of heme-rich erythrocytes, where they can scavenge host heme to meet metabolic needs. Nevertheless, heme biosynthesis in parasite-infected erythrocytes can be potently stimulated by exogenous 5-aminolevulinic acid (ALA), resulting in accumulation of the phototoxic intermediate, protoporphyrin IX (PPIX). Here we use photodynamic imaging, mass spectrometry, parasite gene disruption, and chemical probes to reveal that vestigial host enzymes in the cytoplasm of <italic>Plasmodium</italic>-infected erythrocytes contribute to ALA-stimulated heme biosynthesis and that ALA uptake depends on parasite-established permeability pathways. We show that PPIX accumulation in infected erythrocytes can be harnessed for antimalarial chemotherapy using luminol-based chemiluminescence and combinatorial stimulation by low-dose artemisinin to photoactivate PPIX to produce cytotoxic reactive oxygen. This photodynamic strategy has the advantage of exploiting host enzymes refractory to resistance-conferring mutations.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd><kwd>Human</kwd><kwd>Other</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Paul A Sigala, Is a co-inventor on a provisional patent application entitled Combination Artemisinin and Chemiluminescent Photodynamic Therapy and Uses Therefor&quot;&quot;.</p></fn><fn fn-type="conflict" id="conf3"><p>Daniel E Goldberg, Is a co-inventor on a provisional patent application entitled Combination Artemisinin and Chemiluminescent Photodynamic Therapy and Uses Therefor&quot;&quot;.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></back></article>